In last trading session, Fate Therapeutics Inc (NASDAQ:FATE) saw 4.33 million shares changing hands with its beta currently measuring 1.80. Company’s recent per share price level of $4.09 trading at $0.14 or 3.54% at ring of the bell on the day assigns it a market valuation of $465.52M. That closing price of FATE’s stock is at a discount of -115.89% from its 52-week high price of $8.83 and is indicating a premium of 60.15% from its 52-week low price of $1.63. Taking a look at company’s average trading volume volume of 2.75 million if we extend that period to 3-months.

Fate Therapeutics Inc (NASDAQ:FATE) trade information

Upright in the green during last session for gaining 3.54%, in the last five days FATE remained trading in the red while hitting it’s week-highest on Wednesday, 05/01/24 when the stock touched $4.09 price level, adding 5.54% to its value on the day. Fate Therapeutics Inc’s shares saw a change of 9.36% in year-to-date performance and have moved -4.88% in past 5-day. Fate Therapeutics Inc (NASDAQ:FATE) showed a performance of -39.85% in past 30-days.

Fate Therapeutics Inc (FATE) estimates and forecasts

Statistics highlight that Fate Therapeutics Inc is scoring comparatively lower than the scores of other players of the relevant industry. The company added 136.42% of value to its shares in past 6 months, showing an annual growth rate of -18.29% while that of industry is 12.60. Apart from that, the company came lowering its revenue forecast for fiscal year 2024.

Weighing up company’s earnings over the past 5-year and in the next 5-year periods, we find the company posting an annual earnings growth rate of -6.65% during past 5 years.

FATE Dividends

Fate Therapeutics Inc is more likely to be releasing its next quarterly report in June and investors are confident in the company announcing better current-quarter dividends despite the fact that it has been facing issues arising out of mounting debt.